يعرض 241 - 260 نتائج من 34,008 نتيجة بحث عن '(( 01 1 decrease ) OR ( 50 ((((ns decrease) OR (nn decrease))) OR (we decrease)) ))', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 241
  2. 242
  3. 243
  4. 244

    Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant حسب Ittipat Meewan (7455041)

    منشور في 2019
    "…Several drugs targeting the protease have been developed, but drug-resistant mutant strains emerged. Here, we screened a library and synthesized a novel class of small molecules based on a tryptophan derivative scaffold identified as HCV NS3/4A protease inhibitors that are active against both wild type and mutant form of the protease. …"
  5. 245
  6. 246
  7. 247

    Loss of <i>Nf1</i> increases sleep fragmentation and decreases sleep depth. حسب Elizabeth B. Brown (4582978)

    منشور في 2023
    "…Compared to controls, pan-neuronal knockdown of <i>Nf1</i> has mixed effects on arousal threshold during the day (nsyb/+, <i>P</i><0.2138; <i>Nf1</i><sup>RNAi</sup>/+, <i>P</i><0.0040) and significantly decreases arousal threshold during the night (nsyb/+, <i>P</i><0.0271; <i>Nf1</i><sup>RNAi</sup>/+, <i>P</i><0.00062). …"
  8. 248
  9. 249
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255

    S1 Data - حسب Guoqing Meng (4669774)

    منشور في 2025
    "…Additionally, mice in the PRE and POS groups showed significantly increased levels of IL-10 (<i>P</i> < 0.01), and significantly decreased levels of IL-5, IL-13, MCP-1, eotaxin, and tumor necrosis factor-α (<i>P</i> < 0.01).…"
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases حسب Xiao Li (107004)

    منشور في 2022
    "…CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC<sub>50</sub> = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC<sub>50</sub> = 18 ± 2 to 107 ± 6 nM). …"